All filters
Slidesets
Will HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhD
Presented at:
International Workshop on HBV Cure 2018
Slidesets
What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPH
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Antiviral effect of the RIG-I agonist, Inarigavir | Nezam Afdahl
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Rationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhD
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAg loss in an AAV-HBV mouse model | Yonghong Zhu
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Innate activation with Inactivated parapox viruses for HBV therapy - AIC649 | Daniela Paulsen
Presented at:
International Workshop on HBV Cure 2018
Slidesets
Longer duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors- Daniele Armenia
Presented at:
European HIV Clinical Forum 2018
Slidesets
Integrase inhibitors in specific populations- Women and those aging with HIV- Sharon Walmsley, FRCPC, MD, MSC
Presented at:
European HIV Clinical Forum 2018
Slidesets
Long-acting ARV for treatment & prevention: clinical considerations- Laura Waters, MD, FRCP
Presented at:
European HIV Clinical Forum 2018
Slidesets
Pharmacologic characteristics and delivery options for integrase inhibitors- Courtney Fletcher, PharmD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Intergrase inhibitors- What's new?-Margaret Johnson, MD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Resistance to integrase inhibitors- What clinicians need to know- Roger Paredes, MD, PhD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Reduced drug regimens- What are the data?- Jose Arribas, MD
Presented at:
European HIV Clinical Forum 2018
Slidesets
Switching antiretroviral therapy to safer strategies based on intergrase inhibitors- Pedro Cahn, MD, PhD
Presented at:
European HIV Clinical Forum 2018
Slidesets
CPK/PD Support for a Phase 1 Study of TBA-7371- Jerry Nedelman, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect- Lénaïg Tanneau, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
TPreclinical and Clinical Pharmacokinetics and Pharmacodynamics Analysis of Delamanid- Suresh Mallikaarjun, PHD, FCP
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline- An Vermeulen, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention- Anthony Podany, PharmD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Higher rifampicin and isoniazid concentrations in epithelial lining fluid are associated with improved response to treatment in pulmonary TB- Andrew McCallum, MBChB
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Fluoroquinolones in the treatment of multidrug-resistant tuberculosis: experience from three US TB treatment centers- Charles Peloquin, PharmD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Clofazimine pharmacokinetics in South African patients with drug-resistant tuberculosis-Sean Wasserman, MBChB, MMed
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Cycloserine in TB Patients- Charles Peloquin, PharmD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018
Slidesets
Treatment of Multi-Drug Resistant TB- Robert Horsburgh, MD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018